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Background and Aims: Cold endoscopic mucosal resection (EMR) is being increasingly used for 
large serrated lesions.  We sought to measure residual lesion rates and adverse events after cold 
EMR of large serrated lesions. 
Methods: 
In a single academic center, we retrospectively examined a database of serrated class lesions ≥ 
10 mm removed with cold EMR for safety and efficacy. 
Results: 
Five hundred and sixty-six serrated lesions ≥10 mm in size were removed from 312 patients. We 
successfully contacted 223 patients (71.5%) with no reported serious adverse events that required 
hospitalization, repeat endoscopy, or transfusion. The residual lesion rate per lesion at first 
follow-up colonoscopy was 18 out of 225 (8%; 95% CI, 5-12.1). Lesions with residual were 
larger at polypectomy compared with lesions without recurrence (median, 23 mm vs 16 mm, 
p=0.017). 
Conclusion: 
Cold EMR appears to be safe and effective for the removal of large serrated lesions.  
 
Introduction 
Sessile serrated lesions (SSLs) ≥10 mm in size appear ideal for endoscopic mucosal resection 
(EMR), and resection without electrocautery (cold resection). In a study using standard 
endoscopic resection techniques, serrated class lesions 10 to 20 mm in size were ineffectively 
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resected in almost 50% of cases and were 4 times more likely to be incompletely resected 
compared with adenomas1. However, in 3 studies using EMR with electrocautery for large 
serrated lesions, numerical rates of complete resection at follow-up were better for serrated class 
lesions than conventional adenomas of similar size2-4. Presumably, the use of EMR with a 
submucosal contrast agent, in combination with a high-definition colonoscope, effectively 
allowed endoscopists using EMR to identify all serrated glands and remove them.  
 
An initial study by Tutticci and Hewett5 found that the removal of serrated class lesions could be 
effectively performed using cold EMR techniques, with a residual lesion rate <1%.  In cold 
EMR, the lesion is injected submucosally with fluid containing a contrast agent and then 
removed using a diminutive snare, typically using piecemeal technique and without 
electrocautery. Cold techniques without submucosal injection have also been applied to large 
serrated lesions, with a low recurrence rate6. However, the number of patients reported with cold 
piecemeal resection of large serrated lesions without submucosal injection is smaller. In general, 
cold resection techniques appear safer than resection techniques using electrocautery5-12, with a 
much reduced or negligible risk of delayed postpolypectomy hemorrhage, and negligible risk of  
postpolypectomy syndrome and perforation. 
 
In this report, we describe the adverse event rate in patients undergoing cold EMR and having at 






Given the initial reports of cold EMR, we  converted most serrated lesion resections to cold 
methods in February 2016. We did not use cold EMR for all serrated class lesions ≥10 mm after 
this date (some were removed by cold piecemeal resection without injection, and some serrated 
class lesions ≥20 mm were removed using hot EMR), but most serrated resections  ≥10 mm were 
removed by cold EMR.  We performed a retrospective review of a prospectively maintained 
database of lesions ≥10 mm resected by the senior author (D.K.R) between February 2016 and 
December 2019 using cold EMR at an academic university hospital outpatient endoscopy unit. 
The Institutional Review Board at Indiana University granted permission to review the database 
for the study. 
 
We included serrated class lesions ≥10 mm and excluded conventional adenomas. Patients were 
included irrespective of their anticoagulation status. Some patients had other lesions that were 
removed using electrocautery during the same procedure as the cold EMR and we report the 
adverse events rates separately for this group. We attempted telephone contact to all patients at 
least 30 days after the procedure to ascertain adverse events. In addition, all patients undergoing 
a follow-up examination at our center were queried for  adverse events after the EMR. 
 
Colonoscopic procedures 
All procedures were performed using high definition Olympus 190 series (Olympus Corp, 
Central Valley, Pa, USA) colonoscopes, and a few cases with 180 series instruments. Cold EMR 
was performed by injecting either hydroxyethyl starch mixed with a contrast agent (indigo 
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carmine or methylene blue) or Eleview (Aries Pharmaceutical, San Diego, Calif, USA). 
Epinephrine was not added to the injectate. The snares used were primarily Exacto (U.S. 
Endoscopy, Mentor, Ohio, USA) and the Captivator Cold (Boston Scientific, Marlborough, 
Mass, USA). The general strategy was to resect piecemeal and include a wide margin (up to ≥10 
mm ) of normal tissue around the lesion edge. Lesions were nearly all removed piecemeal. If the 
snare became stuck on submucosal tissue, mechanical traction was used to pull the snare 
through. If intraprocedural arterial bleeding or rapid venous bleeding occurred and persisted, one 
or more clips were placed on the site of active bleeding.  Lesions that were referred were often 
tattooed.  We typically did not tattoo lesions, particularly in SPS patients with multiple lesions.  
We did record size and location of all lesions.  Patients were asked to follow up for surveillance 
after 6 months to 3 years, depending on the size, number, and pathology of the lesions.  We 
located scars by inspection in white light with full colonic distension.  Endocuff Vision 
(Olympus Corp, Center Valley, Pa, USA) was used routinely in follow-up examinations).  
Retroflexion was used in the right and transverse colons as needed to facilitate scar 
identification. Resection sites were inspected with high-definition colonoscopes and near focus 
when available and with both white light and narrow band imaging (NBI).   Residual serrated 
lesion was identified by the surface texture and pit differences compared with normal and scar 
tissue and recognized as residual serrated lesion by features consistent with Type 1 lesions of the 
NICE (NBI International Colorectal Endoscopic classification) 13. Biopsy specimens were taken 
from sites inconsistently and primarily from referred patients traveling significant distances, for 
whom follow-up at our center was less likely.  Biopsies were considered impractical in SPS 
patients with several or more resections, based on the perceived time and cost of biopsy of 
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several or numerous sites.  If no scar could be identified at follow-up, we excluded the lesion 
from calculation of the recurrence rate.  
 
The primary outcomes were the number of patients who reported experiencing adverse events 
within 30 days of the index procedure, and residual lesion rate per polyp at first follow-up 
colonoscopy. Adverse events were defined as bleeding, cramping, emergency department 
visit/hospital visits, or any abdominal pain.  We defined residual lesion as either visual 
confirmation of polyp tissue or histological biopsy of the polypectomy scar site indicating  
serrated histology.   
 
Statistical analysis 
We report descriptive characteristics for patients and polyps. For the primary outcomes of 
adverse events and residual lesion at first follow-up, we report 95% confidence intervals. We 
used Mann-Whitney U test to compare index polyp size between recurrent and nonrecurrent 
lesions (level of significance, 5%). All analyses were performed using SPSS, Version 26 (IBM, 
Armonk, NY, USA).  
 
Results: 
During the study interval, 566 eligible lesions were removed from 312 patients by cold EMR at 
351 examinations. The mean age of the cohort was 62.5 (±10.5) years, and 69.9% were women 
(Table 1). The mean lesion size was 17.2 mm (±6.5), and 88.3% were located proximal to 
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splenic flexure. Five hundred twenty-two were histologically sessile serrated lesions (SSL), 36 
were hyperplastic polyps (HP) and 8 were traditional serrated adenomas (TSA). 
 
Two hundred twenty-three patients (71.5%) of the 312 who underwent cold EMR were contacted 
to ascertain adverse events. Of these, 205 had no other colorectal lesion removed using 
electrocautery at the index procedure. The adverse event rate in this group was 3.9% (95% CI, 
1.9%-7.2%), but none of the events were serious (bleeding which stopped without any 
intervention, n=4; persistent pain relieved without intervention, n=1; felt foggy after procedure, 
n=1; visited emergency department for arrhythmia after the procedure with no intervention 
needed, n=1; minor aspiration during procedure without any intervention, n=1).  
Of the 18 patients who had cold EMR of a serrated lesion ≥10 mm and also had another lesion in 
the colon removed using electrocautery, there were two adverse events (11.1%) (95% CI, 2.4%-
31.1%) (postprocedure chills, n=1; bleeding that stopped without any intervention, n=1). To our 
knowledge, no patient undergoing cold EMR required hospitalization, transfusion, antibiotic 
treatment or repeat colonoscopy to treat bleeding.  
 
Among the 312 study patients, 110 have thus far undergone follow-up colonoscopy at our center 
(median follow-up time, 12.4 months) and were included in the calculation of recurrence.  Five 
additional patients underwent surveillance but were not included in the calculation of residual 
lesion.  Four of these had single lesions resected and no scar or residual lesion was found at 
surveillance.  The fifth excluded patient had 64 lesions resected, and it was not feasible to match 
the resected lesions with the scars.  Of the 225 index lesions removed from these 110 patients,  
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the residual lesion rate at first follow-up was 8% (18/225; 95% CI, 5-12.1). This included a 
visible residual lesion in 13, and 5 lesions with no visible residual lesion but a positive scar 
biopsy. The median size of index lesions with residual lesion was 23 mm compared with 16 mm 
in index lesions without residual (p=0.017). 
 
Seventy-six subjects were diagnosed with serrated polyposis syndrome (SPS) in this cohort. 
These 76 patients had between 1 and 9 EMRs, except one who had 64 EMRs. The mean size of 
the lesions in patients with SPS was 18.5 mm compared with 16.4 mm in patients without SPS 
(p=0.09). The mean number of study lesions from SPS patients was 3.5 and 1.3 in patients 
without SPS (P=0.012). In total, 263 of the 566 study lesions were removed from SPS patients 
(46.5%).  
Discussion 
In this report, we describe our initial experience with adverse events and residual lesion after 
cold EMR of serrated class lesions ≥10 mm in size. More than 90% of the lesions were called 
SSLs by our pathologists, with much smaller numbers of HPs and TSAs. There is significant 
interobserver variation between pathologists in the differentiation of SSLs from hyperplastic 
polyps (HPs), and postpolypectomy surveillance guidelines recommend that HPs ≥10 mm can be 
treated as SSLs14, and warrant closer follow-up than HPs <10 mm in size14. Thus, lesions ≥10 
mm and interpreted pathologically as hyperplastic may have clinical significance.  
 
Our experience confirms that the rate of adverse events after cold EMR of SSLs is minimal and 
appears clinically insignificant compared with historical reports of hot EMR of lesions ≥10 
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mm15, and particularly those ≥20 mm16-19. Arguably, there were no clinically significant adverse 
events from cold EMR in our study. Thus, we can confirm that cold EMR is a safe technique. 
 
From an endoscopic perspective, SSLs appear to be ideal candidates for cold EMR compared 
with conventional adenomas. SSLs, if not subjected to biopsy or partial resection, are nearly 
always devoid of submucosal fibrosis (Figure 1). Anecdotally, they lift extremely well as a class 
of lesions compared with conventional adenomas, when submucosal injection is performed, 
almost regardless of what injection fluid is used. During cold EMR, they separate easily from the 
submucosal tissue, and essentially never have either the bulk nor the fibrosis seen in many 
conventional adenomas that may require electrocautery for successful submucosal snare 
transection.  
The  rate of residual lesion that we identified in this study is higher than some recent reports5, 6, 
20, and comparable to the rates of residual lesion we have described for serrated lesions removed 
by hot EMR at our own center2. The reasons for the higher residual lesion rate of SSLs in this 
study are uncertain and are potentially technical in nature. For example, we did not include 
epinephrine in the injection fluid. Recent studies have shown that intraprocedural hemorrhage is 
associated with an increased risk of residual lesion12, a d anecdotally cold resection without 
epinephrine is clearly associated with a bloodier intraprocedural endoscopic field than when 
epinephrine is included in the injectate. Further, we did encounter some cases of persistent 
bleeding that was more than generalized oozing and included visible arterial hemorrhage, which 
we treated in some cases by clip application (Table 1). Thus, although no randomized controlled 
trial has demonstrated that inclusion of epinephrine in the injectate is associated with a lower risk 
of residual polyp, such a trial may be warranted, and there is at least some evidence suggesting 
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that inclusion of epinephrine is associated with a lower residual lesion rate21.  D spite these 
comments about the potential benefits of including epinephrine in the submucosal injection fluid, 
our anecdotal experience is that the venous oozing that occurs during cold EMR without 
epinephrine, although clearly increased compared with cold EMR with epinephrine, is typically 
self-limited and does not interfere significantly with visibility during resection. Second, although 
we used diminutive snares throughout the study period, we did allow mechanical transection of 
the tissue by pulling it against the colonoscope when the snare became stuck on the submucosa. 
This practice generally leads to the production of “submucosal cords.” Submucosal cords in the 
cold snaring of diminutive polyps have not been associated with any significant occurrence of 
residual polyp tissue on the tip of the cord 22. However, some expert investigators and proponents 
of cold EMR anecdotally try to avoid cord creation during cold EMR23. A prospective study 
examining whether such cords created during cold EMR harbor residual polyp tissue may be 
warranted. We tried to resect the lesions with a substantial margin of normal tissue and inspected 
the lesion margins carefully for residual serrated glands, which seem to be readily apparent after 
contrast injection and inspection using a high definition colonoscope. It is conceivable that other 
technical considerations such as aggressive endoscopic washing of the defect during the 
procedure might lower the residual lesion rate, but this remains uncertain. Another factor that 
could affect the residual lesion rate in our study is that a substantial percentage of the patients 
were referred for resection, and almost all of these patients had the lesion previously biopsied. 
Biopsy of SSLs, particularly when flat, often results in obvious tacking of the lesion to the 
submucosa at the site of the biopsy, which might interfere with the completeness of resection 
using either hot or cold EMR methods. Another potential contributor to the higher rate of 
residual polyp is that the median follow-up in this study was 12.4 months, which is longer than 
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the 6 months in some other studies.  This longer interval might allow more time for a visible 
residual lesion to develop.  Finally, the higher residual rates could reflect differences in 
inspection methods of the polypectomy scar at follow-up.  Currently, all these explanations are  
speculative. Overall, given the residual lesion  rates previously reported for serrated class lesions 
10 to 20 mm using standard polypectomy methods1, and the residual lesion rates for serrated 
class lesions associated with hot EMR2-4, the residual lesion rate reported here, though 
numerically higher than some other recent studies of cold EMR, appears acceptable. However, 
controlled trials comparing hot and cold EMR of both serrated class lesions and conventional 
adenomas seem warranted.  
Limitations of this study include that we did not biopsy all of the EMR scars at follow-up, so that 
the reported rate of residual lesion of 8% likely modestly understates the true rate of residual 
polyp.  Further, many patients in the study have not undergone follow-up yet, or have had 
follow-up at another center.  We did not ask routinely ask patients to return at 6 months for 
follow-up after piecemeal EMR, particularly for lesions <20 mm in size24, and many were asked 
to return in 3 years despite piecemeal resection. Some lesions in the 20 to 30 size range were 
asked to return in 1 year rather than 6 months25. Patients with SPS might be followed at intervals 
of 3 months to 2 years26, depending on the progress in reducing of polyp burden. For these 
reasons, many patients in the series have not had follow-up at our center at this writing.  Further, 
early in the series we did not remove all lesions by cold EMR, with some tendency to use hot 
EMR in very large and referred lesions, so that early on there was some selection bias in which 
lesions were treated by EMR.  Later we moved to cold EMR for the entire set of sessile serrated 
lesions. With regard to adverse events, the study is limited in that about one-third of patients 
were not successfully contacted.  Another limitation is that we did not record which cold snare 
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was used in the resections, so no data comparing the performance of different cold snares are 
available. Finally, the study is from a single center and single endoscopist, and therefore the 
results may not be generalizable. 
 
In conclusion, in a largeseries of cold EMR of serrated lesions ≥10 mm in size, we found no 
significant adverse events, a negligible rate of adverse events and an acceptably low  rate of 
residual polyp at first follow-up. Although randomized controlled trials using an endpoint of 
residual lesion at follow-up still seem warranted, our results support the continued expansion of 
cold EMR in the treatment of sessile serrated lesions.   
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Figure legend 
Figure 1  Cold endoscopic mucosal resection of a sessile serrated lesion. A, 17-mm flat sessile 
serrated lesion when first visualized, with mucus cap. B, Same lesion after subucosal injection 
including indigo carmine as contrast agent. Arrows point to the lesion margin. C, Cap cold snare 
(Boston Scientific, Marlborough, Mass, USA) positioned to take first piece of lesion. Arrow 
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points to margin of lesion. Note several mm margin of normal tissue in snare. D, First piece of 
lesion has been removed. Snare positioned to take second piece of tissue. Arrow is on lesion 
margin. Note margin of normal tissue in snare. E, Residual serrated glands on the margin 
(arrows). Note margin of normal tissue in the resection. F, The defect after resection.  Arr ws
point to submucosal cords that developed during resection. 
Table 1. Patient and polyp characteristics at index procedure and outcomes 
Male gender, n (%) 94 (30.1%) 
Average age, years ± SD 62.5 ± 10.5 
Average polyp size, mm (SD) 17.2 (6.5) 









Polyp location, n (%) 
Right colon (cecum, ICV, Ascending) 
Transverse (hepatic flexure, transverse, 
splenic flexure 






Cytological dysplasia, n (%) 17 (3) 
Number of patients contacted for follow-up 
regarding adverse events, n (%) 
Average time between procedure and time of 
contact, months (min-max) 
Adverse events w/o electrocautery, n/N (%) 









Residual lesion rate per polyp, n/N (%) 18/225 (8.0) 
 
HP, Hyperplastic polyp; ICV, Ileocecal valve, SSP, Sessile serrated polyp; TSA, Traditional serrated 
adenoma 






